Laurent Magy: Influence Statistics

Laurent Magy: Expert Impact

Concepts for which Laurent Magy has direct influence: Dimethyl fumarate , Multiple sclerosis , Natalizumab fingolimod , Fingolimod natalizumab , Trf dmf , Dmf trf , Patients rrms .

Laurent Magy: KOL impact

Concepts related to the work of other authors for which for which Laurent Magy has influence: Multiple sclerosis , Dimethyl fumarate , Natalizumab fingolimod , Cladribine tablets , Sarscov2 infection , Covid19 vaccination , Neurological disorders .

KOL Resume for Laurent Magy

Year

Prominent publications by Laurent Magy

KOL-Index: 13169 . Importance: Risk factors associated with the severity of coronavirus disease 2019 (COVID-19) in patients with multiple sclerosis (MS) are unknown. Disease-modifying therapies (DMTs) may modify the risk of developing a severe COVID-19 infection, beside identified risk factors such as age and comorbidities. Objective: To describe the clinical characteristics and outcomes in patients with MS ...
Known for Clinical Characteristics | Multiple Sclerosis | Covid19 Severity | Patients Age
KOL-Index: 10094 . OBJECTIVE: In this study, we compared the effectiveness of teriflunomide (TRF) and dimethyl fumarate (DMF) on both clinical and MRI outcomes in patients followed prospectively in the Observatoire Français de la Sclérose en Plaques. METHODS: A total of 1,770 patients with relapsing-remitting multiple sclerosis (RRMS) (713 on TRF and 1,057 on DMF) with an available baseline brain MRI were ...
Known for Dimethyl Fumarate | Trf Dmf | Comparative Effectiveness | Multiple Sclerosis
KOL-Index: 9923 . OBJECTIVE: To compare natalizumab and fingolimod on both clinical and MRI outcomes in patients with relapsing-remitting multiple sclerosis (RRMS) from 27 multiple sclerosis centers participating in the French follow-up cohort Observatoire of Multiple Sclerosis. METHODS: Patients with RRMS included in the study were aged from 18 to 65 years with an Expanded Disability Status Scale score of ...
Known for Natalizumab Fingolimod | Patients Rrms | Year Treatment | Comparative Efficacy
KOL-Index: 3168 . OBJECTIVE: To assess disease activity within 12 months after natalizumab (NZ) discontinuation in a large French postmarketing cohort. METHODS: In France, patients exposed at least once to NZ were included in the TYSEDMUS observational and multicenter cohort, part of the French NZ Risk Management Plan. Clinical disease activity during the year following NZ discontinuation was assessed in ...
Known for Natalizumab Withdrawal | Patients Nz | Multiple Sclerosis | 12 Months
KOL-Index: 3039 . BACKGROUND AND PURPOSE: The aim is to describe an uncommon phenotype of hereditary ATTR neuropathy with upper limb onset. METHODS: The French TTR Familial Amyloid Polyneuropathy database was used for a retrospective evaluation of 32 consecutive patients with upper limb onset of the neuropathy (study group) and they were compared to 31 Portuguese early-onset patients and 99 late-onset ...
Known for Upper Limb | Hereditary Transthyretin | Amyloid Neuropathies | Onset Patients

Key People For Dimethyl Fumarate

Top KOLs in the world
#1
Ralf Gold
multiple sclerosis central nervous experimental autoimmune
#2
Ludwig Kappos
multiple sclerosis disability progression magnetic resonance
#3
Katherine T Dawson
multiple sclerosis dimethyl fumarate confirm study
#4
Eva Kubala Havrdová
multiple sclerosis disability progression interferon beta
#5
Amit‐ Bar‐Or
multiple sclerosis central nervous glatiramer acetate
#6
Minhua Yang
multiple sclerosis integrated analysis dimethyl fumarate